Journal
CELLS
Volume 12, Issue 18, Pages -Publisher
MDPI
DOI: 10.3390/cells12182238
Keywords
post-COVID ILD; COVID-19; interstitial lung disease; residual lung abnormalities; pulmonary fibrosis
Categories
Ask authors/readers for more resources
This review discusses the emerging concern of interstitial lung disease (ILD) as a consequence of SARS-CoV-2 infection. The prevailing radiological pattern observed is organizing pneumonia, with ground-glass opacities and reticulation frequently reported. Longitudinal studies reveal a complex trajectory, with some patients showing improvement in lung function and radiographic abnormalities over time while others display more static fibrotic changes. Age, disease severity, and male sex are emerging as risk factors for residual lung abnormalities. Further research and understanding of the relationship between post-COVID ILD and idiopathic pulmonary fibrosis (IPF) genetics are crucial for guiding clinical decisions and improving outcomes for patients.
As the world transitions from the acute phase of the COVID-19 pandemic, a novel concern has arisen-interstitial lung disease (ILD) as a consequence of SARS-CoV-2 infection. This review discusses what we have learned about its epidemiology, radiological, and pulmonary function findings, risk factors, and possible management strategies. Notably, the prevailing radiological pattern observed is organising pneumonia, with ground-glass opacities and reticulation frequently reported. Longitudinal studies reveal a complex trajectory, with some demonstrating improvement in lung function and radiographic abnormalities over time, whereas others show more static fibrotic changes. Age, disease severity, and male sex are emerging as risk factors for residual lung abnormalities. The intricate relationship between post-COVID ILD and idiopathic pulmonary fibrosis (IPF) genetics underscores the need for further research and elucidation of shared pathways. As this new disease entity unfolds, continued research is vital to guide clinical decision making and improve outcomes for patients with post-COVID ILD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available